NASDAQ · Biotechnology

Kalaris Therapeutics, Inc. (KLRS) Stock

$1.91 -4.50% NASDAQ: KLRS Healthcare

Valuation

MetricValue
Price$1.91
Market Cap$41.71M
P/E Ratio-1.38
P/B Ratio1.15
P/S Ratio0.00
EPS (TTM)$-1.52
52-Week High$11.88
52-Week Low$1.90
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-71.71%
ROA-44.47%
ROCE-52.60%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio11.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-170.0M$-14.0M$-13.0M$-55.0M$-46.0M
Net Profit$-172.0M$-15.0M$-15.0M$-59.0M$-43.0M
EPS$-63.00$-50.62$-42.09$-11.73$-2.85
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$287.0M$4.0M$3.0M$119.0M$122.0M
Total Liabilities$61.0M$34.0M$48.0M$5.0M$43.0M
Cash$202.0M$3.0M$3.0M$118.0M$98.0M
Borrowings$30.0M$3.0M$0$0$1.0M

Latest News

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board Insider Monkey · Jul 14, 2026 Kalaris Appoints Laurie Keating to Board of Directors GlobeNewswire · Jul 6, 2026 Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling GlobeNewswire · Jun 23, 2026 TD Cowen Initiates Kalaris Therapeutics at Buy MT Newswires · Jun 15, 2026 Kalaris to Present at Clinical Trials at the Summit 2026 GlobeNewswire · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-106.0M$-10.0M$-14.0M$-68.0M$-43.0M
Investing Cash Flow$186.0M$0$0$95.0M$-20.0M
Financing Cash Flow$0$0$2.0M$0$102.0M
Net Cash Flow$79.0M$3.0M$0$28.0M$-20.0M
Free Cash Flow$-106.0M$-10.0M$-14.0M$-68.0M$-43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.42
FCF Yield-74.93%
Quick Ratio10.98
Interest Coverage-46.00
Return 1Y94.58%
Return 3Y-94.20%
Return 5Y-98.85%

Ownership

Insiders Held8.81%
Institutions Held77.88%
Institutions Float Held85.40%
Institutional HolderSharesReport Date
Samsara BioCapital, LLC12,948,0812026-03-31
RTW Investments LP1,300,0002026-03-31
Paradigm Biocapital Advisors LP700,0002026-03-31
Alyeska Investment Group, L.p.572,6872026-03-31
Siren, L.L.C.435,7982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $342.94 -0.15% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $533.52 +0.84% 28.68 $3.96T 0.76%
GOOGLAlphabet Inc. $344.18 +1.05% 16.94 $4.19T 0.26%
AMZNAmazon.com, Inc. $262.45 +4.98% 19.82 $2.83T 0.00%
METAMeta Platforms, Inc. $705.44 -0.55% 27.93 $1.80T 0.28%

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. is led by CEO Andrew Oxtoby, employs 14 people, headquartered in US, publicly traded since 2020.

Kalaris Therapeutics, Inc. (KLRS) stock trades at $1.91 with a market capitalization of $41.71M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.38, reflecting a net loss over the last twelve months, price-to-book of 1.15, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.90 and $11.88, and currently trades 83.9% below its 52-week high.

On profitability, Kalaris Therapeutics, Inc. generates a return on equity (ROE) of -71.71% (negative, reflecting a net loss), return on capital employed of -52.60%.

Kalaris Therapeutics, Inc. (KLRS) — frequently asked questions

What is Kalaris Therapeutics, Inc. (KLRS) stock price today?

Kalaris Therapeutics, Inc. (KLRS) is currently trading at $1.91, down 4.5% today.

What is KLRS P/E ratio?

Kalaris Therapeutics, Inc.'s P/E ratio is -1.38. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is KLRS return on equity (ROE)?

Kalaris Therapeutics, Inc.'s return on equity (ROE) is -71.71%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Kalaris Therapeutics, Inc.'s market cap?

Kalaris Therapeutics, Inc. has a market capitalization of $41.71M.

Related Healthcare Stocks

LLY Eli Lilly and Company $1240.34 -1.33% JNJ Johnson & Johnson $253.79 -0.69% ABBV AbbVie Inc. $282.78 -0.92% UNH UnitedHealth Group Incorporated Common Stock (DE) $406.88 +1.36% MRK Merck & Company, Inc. Common Stock (new) $143.67 -1.56% NVS Novartis AG $150.20 -0.28% AZN AstraZeneca PLC $163.95 -0.88% TMO Thermo Fisher Scientific Inc $679.38 -1.54% AMGN Amgen Inc. $424.94 -1.75% GILD Gilead Sciences, Inc. $153.07 -2.00% ABT Abbott Laboratories $104.06 -0.79% NVO Novo Nordisk A/S $38.42 -1.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.